Search
Related
DIAPH3 governs the cellular transition to the amoeboid tumour phenotype.
Hager MH, Morley S, Bielenberg DR, Gao S, Morello M, Holcomb IN, Liu W, Mouneimne G, Demichelis F, Kim J, Solomon KR, Adam RM, Isaacs WB, Higgs HN, Vessella RL, Di Vizio D, Freeman MR.
EMBO Mol Med. 2012 May 16. doi: 10.1002/emmm.201200242. [Epub ahead of print
22593025
[PubMed - as supplied by publisher] nohighlight
Related citations
Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
Gorges TM, Tinhofer I, Drosch M, Roese L, Zollner TM, Krahn T, von Ahsen O.
BMC Cancer. 2012 May 16;12(1):178. [Epub ahead of print
22591372
[PubMed - as supplied by publisher] Free Article nohighlight
Related citations
Targeted therapy for triple-negative breast cancer: where are we?
Duffy MJ, McGowan PM, Crown J.
Int J Cancer. 2012 May 14. doi: 10.1002/ijc.27632. [Epub ahead of print
22581656
[PubMed - as supplied by publisher] nohighlight
Related citations
MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.
Kufe DW.
Oncogene. 2012 May 14. doi: 10.1038/onc.2012.158. [Epub ahead of print
22580612
[PubMed - as supplied by publisher] nohighlight
Related citations
Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.
Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, Macbeath G, Yaffe MB.
Cell. 2012 May 11;149(4):780-94
22579283
[PubMed - in process] nohighlight
Related citations
A Miniaturized Ligand Binding Assay for EGFR.
Schwenk JM, Poetz O, Zeillinger R, Joos TO.
Int J Proteomics. 2012;2012:247059. Epub 2012 Apr 8
22577549
[PubMed - in process] Free PMC Article nohighlight
Related citations
Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
Luedke E, Cristina Jaime-Ramirez A, Bhave N, Carson WE 3rd.
J Immunother. 2012 Jun;35(5):367-73
22576341
[PubMed - in process] nohighlight
Related citations
Insulin-like Growth Factor-1 Receptor (IGF-1R) Kinase Inhibitors in Cancer Therapy: Advances and Perspectives.
Xue M, Cao X, Zhong Y, Kuang D, Liu X, Zhao Z, Li H.
Curr Pharm Des. 2012 May 7. [Epub ahead of print
22571659
[PubMed - as supplied by publisher] nohighlight
Related citations
Novel targeted agents for the treatment of advanced breast cancer.
de la Vega M, Díaz-Cantón E, Alvarez RH.
Future Med Chem. 2012 May;4(7):893-914
22571614
[PubMed - in process] nohighlight
Related citations
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
Ren S, Chen X, Kuang P, Zheng L, Su C, Li J, Li B, Wang Y, Liu L, Hu Q, Zhang J, Tang L, Li X, Zhou C, Schmid-Bindert G.
Cancer. 2012 May 8. doi: 10.1002/cncr.27603. [Epub ahead of print
22569898
[PubMed - as supplied by publisher] nohighlight
Related citations
Novel Benzimidazole analogues as inhibitors of EGFR tyrosine kinase.
Yadav S, Sinha D, Singh SK, Singh VK.
Chem Biol Drug Des. 2012 May 5. doi: 10.1111/j.1747-0285.2012.01407.x. [Epub ahead of print
22564276
[PubMed - as supplied by publisher] nohighlight
Related citations
Expression of activated type I receptor tyrosine kinases in early breast cancer.
Spears M, Pederson HC, Lyttle N, Gray C, Quintayo MA, Brogan L, J Thomas JS, Kerr GR, Jack WJ, Kunkler IH, Cameron DA, Chetty U, Bartlett JM.
Breast Cancer Res Treat. 2012 May 5. [Epub ahead of print
22562124
[PubMed - as supplied by publisher] nohighlight
Related citations
Biomarkers Characterization of Circulating Tumour Cells in Breast Cancer Patients.
Nadal RM, Fernandez A, Sanchez-Rovira P, Salido M, Rodriguez M, Garcia-Puche JL, Macia M, Coromines JM, Delgado-Rodriguez M, Gonzalez L, Albanell J, Fernandez M, Sole F, Lorente JA, Serrano MJ.
Breast Cancer Res. 2012 May 3;14(3):R71. [Epub ahead of print
22554015
[PubMed - as supplied by publisher] nohighlight
Related citations
Bisphenol A Induces Gene Expression Changes and Proliferative Effects through GPER in Breast Cancer Cells and Cancer-Associated Fibroblasts.
Pupo M, Pisano A, Lappano R, Santolla MF, De Francesco EM, Abonante S, Rosano C, Maggiolini M.
Environ Health Perspect. 2012 May 2. [Epub ahead of print
22552965
[PubMed - as supplied by publisher] Free Article nohighlight
Related citations
Phthalates stimulate the epithelial to mesenchymal transition through an HDAC6-dependent mechanism in human breast epithelial stem cells.
Hsieh TH, Tsai CF, Hsu CY, Kuo PL, Lee JN, Chai CY, Hou MF, Chang CC, Ko YC, Tsai EM.
Toxicol Sci. 2012 May 2. [Epub ahead of print
22552774
[PubMed - as supplied by publisher] nohighlight
Related citations
Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation.
Hutti JE, Pfefferle AD, Russell SC, Sircar M, Perou CM, Baldwin AS.
Cancer Res. 2012 May 2. [Epub ahead of print
22552288
[PubMed - as supplied by publisher] nohighlight
Related citations
Triple Negative Breast Cancer: A Brief Review of its Characteristics and Treatment Options.
Griffths CL, Olin JL.
J Pharm Pract. 2012 May 2. [Epub ahead of print
22551559
[PubMed - as supplied by publisher] nohighlight
Related citations
Tumour characteristics among women with very low-risk breast cancer.
Narod SA, Valentini A, Nofech-Mozes S, Sun P, Hanna W.
Breast Cancer Res Treat. 2012 May 1. [Epub ahead of print
22547106
[PubMed - as supplied by publisher] nohighlight
Related citations
Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M, Rocha RM, Soares FA, Gobbi H.
Pathology. 2012 Apr 25. [Epub ahead of print
22544210
[PubMed - as supplied by publisher] nohighlight
Related citations
Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
Wen YH, Ho A, Patil S, Akram M, Catalano J, Eaton A, Norton L, Benezra R, Brogi E.
Breast Cancer Res Treat. 2012 Apr 27. [Epub ahead of print
22538771
[PubMed - as supplied by publisher] nohighlight
Related citations